The Week In Review provides an overview of the past week’s top healthcare content, including industry news and trends, Mayo Clinic and Mayo Medical Laboratories news and upcoming events. Top highlights this week include experimental gene therapy, health care law, the flu, Mayo Clinic Destination Medical Center and a new laboratory test.
Currently, several United States Food and Drug Administration (FDA)-approved specific inhibitors of certain molecular targets are effective for treating patients with non-small cell lung cancer (NSCLC). Patients should undergo EGFR and ALK testing on their tumors using FFPE tissues.
With Thanksgiving right around the corner, turkey is on everyone’s mind. To make this time of year a fun and safe one, the Centers for Disease Control and Prevention (CDC) has compiled a few Turkey Basics when it comes to preparing food for the holidays.
Mayo Clinic Care Network adds first Colorado member, Aspen Valley Hospital. Aspen Valley Hospital is a 25-bed critical access hospital that has received national awards for patient satisfaction from Avatar International and was recently named one of the top 20 Critical Access Hospitals in the country.
Mayo Clinic and Mayo Medical Laboratories have signed a collaboration agreement with bioTheranostics to offer CancerTYPE ID® molecular cancer classification test, as part of its surgical pathology consultations, to aid in the management of patients with metastatic cancer.
Melanoma comprises only 10 percent of all skin cancers, but is responsible for approximately 90 percent of all skin-cancer mortality. Mayo Medical Laboratories’ melanoma FISH assay assists in the diagnosis of malignant melanoma, differentiating malignant melanoma from benign melanocytic lesions.
Systems engineers from the Mayo Clinic Department of Laboratory Medicine and Pathology (DLMP) were recently interviewed by “Clinic Lab Products” for its October coverage of Lean and Six Sigma laboratory solutions. Interviewed for the article were Rich Carlson and Matt A. Clark.
Clostridium difficile, an anaerobic spore-forming gram-positive bacillus, is the most important cause of antibiotic-associated diarrhea and pseudomembranous colitis. Polymerase chain reaction (PCR) assays have been developed to detect genetic markers in the PaLoc region of C difficile. While it is the most efficient direct method for laboratory diagnosis of C difficile infection, some laboratories may prefer the algorithmic approach using PCR as a confirmatory test for the presence of toxin.
Jaundice is a very common condition in newborn infants that is most often benign. However, acute and chronic bilirubin encephalopathy (acute or chronic neurologic damage resulting from high serum bilirubin levels) does still occur. Mayo Clinic used a screening algorithm to determine how to best use and interpret TcB values from healthy newborns.
Lyme disease is a tick-borne illness that is endemic in certain areas of the United States, including the Northeast and Upper Midwest. In several situations, laboratory testing is not recommended. However, laboratory diagnosis of Lyme disease is most commonly achieved by serologic testing, which should be limited to those persons with an appropriate exposure history and objective clinical findings. When serology is ordered, testing should be performed using the two-step approach as recommended by the CDC.
COLA, a leading laboratory accreditor, announced that it is expanding its educational offerings by collaborating with Mayo Medical Laboratories, a global reference laboratory operating within Mayo Clinic’s Department of Laboratory Medicine and Pathology. Under the agreement, COLA is now providing a convenient link to Mayo Medical Laboratories’ test utilization website directly from www.cola.org and the accreditor’s educational portal, www.labuniversity.org. Read more for full details.
Researchers at Mayo Clinic Cancer Center have developed new guidelines to treat recently diagnosed multiple myeloma patients who are not participating in clinical trials. The guidelines give physicians practical, easy to follow recommendations for providing initial therapy, stem cell transplant and maintenance therapy. The guidelines are published in the current issue of the journal Mayo Clinic Proceedings and represent a consensus opinion of hematologists at Mayo Clinic Cancer Center sites in Minnesota, Florida and Arizona.
Mayo Clinic gastroenterologist and celiac disease expert Joseph Murray, M.D., discusses a recent article published in the Journal of Agricultural and Food Chemistry that studied the possibility that increased gluten content in wheat from wheat breeding has led to the increase of celiac disease seen during the latter part of the twentieth century.